To provide participants with recommendations for how to modify current indication prioritization best practices to improve strategic decision making.
•Participants will be introduced to a new and robust framework for indication prioritization that has resulted in more balanced and actionable assessments of individual indications by focusing not only on feasibility, but also post launch differentiation and value creation
•The result of this change in approach has been improved decision making and higher corporate valuations with less risk – cases will be discussed
•Moderators from Syneos Consulting will lead the group through the following discussions:
- -Aligning to a common definition and objectives for indication prioritization
- -Discussing current best practices for indication prioritization and pitfalls
- -Introducing new clinical evaluation dimensions to improve assessments of clinical feasibility
- -Introducing TPP development and testing as an integral stage in prioritizing target indications
- -Defining ways of working with clinical teams to ensure appropriate assumptions relating to clinical strategies and plans are developed
- -Understanding new capabilities a company may need to build or partner to enable recommended changes
